New ‘PAGER’ technology could transform cell therapies
Researchers at Stanford University have built a new synthetic receptor with broad potential to programme cell activity, including immune response and neurological signalling.
Detailed in a paper published in Nature, the new synthetic receptor accommodates a broader range of inputs and produces a more diverse set of outputs.
The innovation, called ‘Programmable Antigen-gated G protein-coupled Engineered Receptors’ (PAGER), is built around G protein-coupled receptors. The researchers demonstrated PAGER’s versatility by successfully controlling neuronal activity, triggering immune responses, and delivering therapeutic treatments in lab experiments.
“I think PAGER has potential for impact, both in the G protein coupled receptor biology field, and in synthetic circuits or cell-based therapies,” said Alice Ting, Professor of Genetics at the School of Medicine and of biology in the School of Humanities and Sciences and senior author of the paper. “When you put a technology out there, it’s always exciting to see all the creative ways that people use and transform the technology in ways that you never even imagined. There’s so much more that’s possible.”
The researchers used PAGER to alter neuronal activity in a cell culture and a section of mouse brain, control T-cell migration, change the inflammatory state of macrophages (a type of immune cell), and secrete therapeutic antibodies in response to the presence of tumour antigens.
“We didn’t expect all four applications to work right away, but they did, which made me feel really good about the technology,” said Ting. “We didn’t have any application where we tried it and it didn’t work – which is not a promise to everyone that it’ll work for them – but it was robust.”
The research stemmed in part from the NeuroOmics Initiative supported by Stanford’s Wu Tsai Neurosciences Institute.
Diana Spencer, Senior Digital Content Editor, DDW
